Ozempic Works Best for 'See-Food' Eaters, Japan Study Finds
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Researchers at Kyoto University and Gifu University tracked 92 people with type 2 diabetes in Gifu Prefecture, Japan, over their first 12 months of GLP-1 therapy, measuring weight, body composition, blood glucose, and eating behaviors at baseline, 3 months, and 12 months.
- External eaters — participants who overeat because food looks or smells appealing — showed the greatest improvements in both weight loss and blood glucose control, with reductions in external-eating behavior sustained through the full year.
- Emotional eaters, who eat in response to stress or negative feelings, saw their eating patterns return to near-baseline levels by month 12 and did not experience the same long-term treatment benefits as external eaters.
- Prof. Daisuke Yabe, senior author from Kyoto University, said pre-treatment assessment of eating behavior patterns 'may help predict who will benefit most from GLP-1 receptor agonist therapy,' since the drugs target externally triggered overeating more than emotionally driven eating.
- Dr. Takehiro Kato of Gifu University suggested emotional eaters 'may require additional behavioral or psychological support' beyond GLP-1 medication to sustain results.
- The study, published in Frontiers in Clinical Diabetes and Healthcare, noted key limitations: it was observational, relied partly on self-reported data, and participants may have been especially motivated, meaning the findings remain preliminary pending larger randomized trials.
Why it matters: With GLP-1 prescriptions soaring and treatment costs running high, a simple pre-treatment eating-behavior questionnaire could help clinicians identify the patients most likely to respond to Ozempic and similar drugs — and flag emotional eaters, roughly half of the 92-person cohort, who may need psychological support alongside medication rather than medication alone. The mechanistic insight is concrete: GLP-1 drugs blunt sensory-driven appetite far more effectively than stress-driven eating, which has direct implications for patient counseling and treatment planning.
